Haemonetics Corporation $HAE Shares Acquired by Peregrine Capital Management LLC

Peregrine Capital Management LLC lifted its position in shares of Haemonetics Corporation (NYSE:HAE) by 47.4% during the 1st quarter, HoldingsChannel reports. The fund owned 42,163 shares of the medical instruments supplier’s stock after purchasing an additional 13,553 shares during the period. Peregrine Capital Management LLC’s holdings in Haemonetics were worth $2,376,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Central Pacific Bank Trust Division increased its stake in shares of Haemonetics by 2.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock valued at $713,000 after purchasing an additional 188 shares in the last quarter. Quantinno Capital Management LP boosted its position in Haemonetics by 9.0% during the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock worth $261,000 after purchasing an additional 289 shares in the last quarter. UMB Bank n.a. boosted its position in Haemonetics by 110.9% during the fourth quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 306 shares in the last quarter. Cardinal Capital Management grew its holdings in Haemonetics by 1.5% in the fourth quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock valued at $1,799,000 after purchasing an additional 321 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new stake in Haemonetics in the fourth quarter valued at approximately $26,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Stock Performance

Shares of NYSE:HAE opened at $74.93 on Friday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The business’s 50 day moving average price is $66.55 and its 200-day moving average price is $66.49. The firm has a market capitalization of $3.41 billion, a PE ratio of 37.09, a P/E/G ratio of 1.51 and a beta of 0.52. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million during the quarter, compared to the consensus estimate of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, equities research analysts expect that Haemonetics Corporation will post 5.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on HAE shares. Mizuho upped their target price on Haemonetics from $70.00 to $85.00 and gave the stock an “outperform” rating in a research note on Monday, June 15th. Bank of America raised shares of Haemonetics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. BTIG Research reissued a “buy” rating and issued a $84.00 price target on shares of Haemonetics in a report on Friday, June 26th. Robert W. Baird set a $67.00 price objective on shares of Haemonetics in a research report on Friday, May 8th. Finally, Weiss Ratings raised shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and an average target price of $78.33.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.